Thomas Rutherford

Thomas Rutherford, PhD, MD

Director, College of Medicine Obstetrics & Gynecology

Professor & Division Director, College of Medicine Obstetrics & Gynecology

Contact Info 2 Tampa General Circle
6th Floor
Tampa FL 33606

Academic Email: tjrutherford@health.usf.edu

Academic Phone:(813) 844-7585

View My C.V.

Education

  • PhD, Molecular Biology, University of Ohio at Toledo, 1986
  • MD, Medicine, University of Toledo, 1985

Recent Publications

  • Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 145(1) : 122-129, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28190649
  • von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecologic oncology. 144(3) : 459-467, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28089376
  • Black JD, Roque DM, Pasternak MC, Buza N, Rutherford TJ, Schwartz PE, McCarthy S, Ratner E. A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 25(5) : 792-7, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25790042
  • English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 121(3) : 403-12, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25251053
  • Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical & experimental metastasis. 32(1) : 29-38, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25398397
  • Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Brower SL, Powell MA, Rutherford TJ, Coleman RL. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. Gynecologic oncology. 136(1) : 94-8, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25462203
  • Seagle BL, Dawson M, Samuelson R, Chacho MS, Rutherford TJ, Shahabi S. Feasibility, Sensitivity, and Specificity of Postprocedure Peritoneal Cytology. Reproductive sciences (Thousand Oaks, Calif.). 22(7) : 808-13, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25488943
  • Erekson EA, Fried TR, Martin DK, Rutherford TJ, Strohbehn K, Bynum JP. Frailty, cognitive impairment, and functional disability in older women with female pelvic floor dysfunction. International urogynecology journal. 26(6) : 823-30, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25516232
  • Wang Z, Risch H, Lu L, Irwin ML, Mayne S, Schwartz P, Rutherford T, De Vivo I, Yu H. Joint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk. Scientific reports. 5: 15582, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26498156
  • Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic oncology. 139(1) : 112-7, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26260909
  • Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics. Gynecologic and obstetric investigation. , 2015. http://www.ncbi.nlm.nih.gov/pubmed/26067608
  • Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer. International journal of cancer. 137(11) : 2618-29, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26060989
  • Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal of contemporary brachytherapy. 7(1) : 35-40, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25829935
  • Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 137(3) : 386-91, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25818403
  • Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecologic oncology. 137(3) : 392-400, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25792179
  • Erekson E Fried T Martin D Rutherford T Strohbehn K Bynum J. Frailty, cognitive impairment, and functional disability in older women seeking treatment for pelvic floor disorders. Int UroGyn J.. 26(6) : 823-830., 2015.
  • Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. British journal of cancer. 111(9) : 1750-6, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25268372
  • Ishiguro K, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Zhu YL, Sartorelli AC, Rutherford TJ, Ratner ES. Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes. Biochemical pharmacology. 91(3) : 312-22, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25130544
  • Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 24(3) : 528-33, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24557436
  • Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecologic oncology. 135(2) : 312-7, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25172762
  • Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of body mass index on surgical outcomes and analysis of disease recurrence for patients with endometrial cancer undergoing robotic-assisted staging. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 24(6) : 1118-25, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24927247
  • Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & experimental metastasis. 31(1) : 101-10, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24005572
  • English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecologic oncology. 131(3) : 753-8, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24012800
  • Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. British journal of cancer. 109(2) : 462-71, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23807163
  • Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, Schwartz PE. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal of surgical oncology. 107(2) : 195-200, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22648987
  • Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, Yin G, Rimm DL, Holmberg J, Alvero A, Silasi DA. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reproductive sciences (Thousand Oaks, Calif.). 20(5) : 605-15, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23171677
  • Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 110(8) : 2916-21, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23359684
  • Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer. 119(14) : 2582-92, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23585021
  • English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). American journal of obstetrics and gynecology. 209(5) : 465.e1-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23891627
  • Ishiguro K, Shyam K, Penketh PG, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES. Expression of O(6)-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal Tissue. Journal of cancer therapy. 4(4) : 919-931, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23946891
  • Rutherford T, Orr J, Grendys E, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecologic oncology. 131(2) : 362-7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23954900
  • ElSahwi KS, Hooper C, De Leon MC, Gallo TN, Ratner E, Silasi DA, Santin AD, Schwartz PE, Rutherford TJ, Azodi M. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecologic oncology. 124(2) : 260-4, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22036203
  • Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecologic oncology. 125(1) : 231-6, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22209775
  • Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 31(42) : 4559-66, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22139083
  • Roberts KE, Solomon D, Mirensky T, Silasi DA, Duffy AJ, Rutherford T, Longo WE, Bell RL. Pure transvaginal appendectomy versus traditional laparoscopic appendectomy for acute appendicitis: a prospective cohort study. Annals of surgery. 255(2) : 266-9, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22167005
  • Nelson WK, Formica RN, Cooper DL, Schwartz PE, Rutherford TJ. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 18(3) : 323-32, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22331238
  • Guzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, Cocco E, Betti M, Todeschini P, Gasparrini S, Schwartz PE, Rutherford TJ, Angioli R, Pecorelli S, Santin AD. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 31(3) : 211-21, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22498937
  • Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British journal of cancer. 106(9) : 1543-50, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22531721
  • El-Sahwi KS, Illuzzi J, Varughese J, Carusillo N, Ratner ES, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. A survey of gynecologic oncologists regarding the end-of-life discussion: a pilot study. Gynecologic oncology. 124(3) : 471-3, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22014628
  • Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AD. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor. Clinical & experimental metastasis. 28(7) : 689-700, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21725665
  • Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Lockwood CJ, Santin AD. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC cancer. 11: 263, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21693061
  • Kelly MG, Mor G, Husband A, O'Malley DM, Baker L, Azodi M, Schwartz PE, Rutherford TJ. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 21(4) : 633-9, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21412168
  • Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecologic oncology. 122(1) : 171-7, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21453957
  • Leizer AL, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, Rutherford T, Mor G. Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells. American journal of reproductive immunology (New York, N.Y. : 1989). 65(4) : 438-47, 2011. http://www.ncbi.nlm.nih.gov/pubmed/20825380
  • Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecologic oncology. 122(2) : 366-71, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21571355
  • Bellone M, Cocco E, Varughese J, Bellone S, Todeschini P, El-Sahwi K, Carrara L, Guzzo F, Schwartz PE, Rutherford TJ, Pecorelli S, Marshall DJ, Santin AD. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 21(6) : 1084-90, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21633302
  • Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer. 117(24) : 5519-28, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21692061
  • Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. American journal of obstetrics and gynecology. 205(6) : 567.e1-7, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21889762
  • Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, Schwartz PE, Rutherford TJ, Santin AD. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 21(9) : 1613-21, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21892093
  • Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. Journal of translational science. 2(2) : 117-124, 2011. http://www.ncbi.nlm.nih.gov/pubmed/27076919
  • Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British journal of cancer. 105(8) : 1176-82, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21915118
  • Elsahwi KS, Barber E, Illuzzi J, Buza N, Ratner E, Silasi DA, Santin AD, Azodi M, Schwartz PE, Rutherford TJ. The significance of perineural invasion in early-stage cervical cancer. Gynecologic oncology. 123(3) : 561-4, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21968340
  • Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. Journal of experimental & clinical cancer research : CR. 30: 106, 2011. http://www.ncbi.nlm.nih.gov/pubmed/22075385
  • Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer. 117(14) : 3163-72, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21246534
  • Lu L, Risch H, Irwin ML, Mayne ST, Cartmel B, Schwartz P, Rutherford T, Yu H. Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. International journal of cancer. 129(5) : 1237-43, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21387312
  • Steffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T, Mor G. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. Journal of oncology. 2011: 620523, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21904548
  • Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 20(9) : 1440-7, 2010. http://www.ncbi.nlm.nih.gov/pubmed/21370592
  • Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. American journal of obstetrics and gynecology. 203(6) : 582.e1-7, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20870202
  • Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. British journal of cancer. 103(6) : 812-9, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20700124
  • Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer research. 70(16) : 6509-15, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20647319
  • Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC cancer. 10: 349, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20598131
  • Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecologic oncology. 118(3) : 251-7, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20542546
  • Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal of clinical pathology. 63(6) : 544-7, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20418225
  • Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. American journal of obstetrics and gynecology. 203(2) : 162.e1-8, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20417484
  • Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene. 29(24) : 3545-53, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20400975
  • Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P. HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology. 56(2) : 269-73, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20102407
  • El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Molecular cancer therapeutics. 9(1) : 57-66, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20053761
  • El-Sahwi K Bellone S Cocco E Cargnelutti M Cassagrande F Bellone M Abu-Khalaf M Buza N Tavassoli FA Hui P Silasi DA Azodi M Schwartz PE Rutherford TJ Percorelli S Santin AD. In vitro activity of Pertuzumab in combination with Trastuzumab in uterine serous papillary adenocarcinoma. Br J. Cancer.. 1020: 134-143., 2010.
  • Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer. 116(4) : 843-51, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20041483
  • Sadeghi H, Rutherford T, Rackow BW, Campbell KH, Duzyj CM, Guess MK, Kodaman PH, Norwitz ER. Cesarean scar ectopic pregnancy: case series and review of the literature. American journal of perinatology. 27(2) : 111-20, 2010. http://www.ncbi.nlm.nih.gov/pubmed/19504427
  • Richter CE, Qian B, Martel M, Yu H, Azodi M, Rutherford TJ, Schwartz PE. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecologic oncology. 114(1) : 99-104, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19410280
  • Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 19(5) : 860-6, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19574774
  • Ratner ES, Toy E, O'Malley DM, McAlpine J, Rutherford TJ, Azodi M, Higgins SA, Schwartz PE. Brain metastases in epithelial ovarian and primary peritoneal carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 19(5) : 856-9, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19574773
  • Bellone S Anfossi S OBrien TJ Cannon MJ Silasi DA Azodi M Schwartz PE Rutherford TJ Pecorelli S Santin AD. Generation of TADG-12-specific Cytotoxic T Lymphocytes in Human Leukocyte Antigen-A2.1 positive healthy Donors and Patients with Advanced Ovarian Cancer. Cancer.. 115(4) : 800-11., 2009.
  • Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. Journal of virology. 83(13) : 6779-89, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19386711
  • Silasi DA, Alvero AB, Rutherford TJ, Brown D, Mor G. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert opinion on pharmacotherapy. 10(6) : 1059-67, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19364253
  • Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer. 115(11) : 2453-63, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19322891
  • Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell cycle (Georgetown, Tex.). 8(1) : 158-66, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19158483
  • Bernstein EM, Tate A, Silasi DA, Rutherford T. Benign multicystic mesothelioma: a case report of three sisters. Rare tumors. 1(2) : e46, 2009. http://www.ncbi.nlm.nih.gov/pubmed/21139925
  • Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. American journal of obstetrics and gynecology. 200(1) : 75.e1-10, 2009. http://www.ncbi.nlm.nih.gov/pubmed/18976739
  • Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British journal of cancer. 101(2) : 335-41, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19536090
  • Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene. 27(34) : 4712-23, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18408758
  • McAlpine JN, Hodgson EJ, Abramowitz S, Richman SM, Su Y, Kelly MG, Luther M, Baker L, Zelterman D, Rutherford TJ, Schwartz PE. The incidence and risk factors associated with postoperative delirium in geriatric patients undergoing surgery for suspected gynecologic malignancies. Gynecologic oncology. 109(2) : 296-302, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18374970
  • Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G. Diagnostic markers for early detection of ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(4) : 1065-72, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18258665
  • Alvero AB, Kelly M, Rossi P, Leiser A, Brown D, Rutherford T, Mor G. Anti-tumor activity of phenoxodiol: from bench to clinic. Future oncology (London, England). 4(4) : 475-82, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18684059
  • Agarwal R, Whang DH, Alvero AB, Visintin I, Lai Y, Segal EA, Schwartz P, Ward D, Rutherford T, Mor G. Macrophage migration inhibitory factor expression in ovarian cancer. American journal of obstetrics and gynecology. 196(4) : 348.e1-5, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17403417
  • Silasi DA, Illuzzi JL, Kelly MG, Rutherford TJ, Mor G, Azodi M, Schwartz PE. Carcinosarcoma of the ovary. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 18(1) : 22-9, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17451459
  • Beeghly AC, Katsaros D, Wiley AL, Rigault de la Longrais IA, Prescott AT, Chen H, Puopolo M, Rutherford TJ, Yu H. IGF-II promoter methylation and ovarian cancer prognosis. Journal of cancer research and clinical oncology. 133(10) : 713-23, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17569086
  • Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(33) : 5172-9, 2007. http://www.ncbi.nlm.nih.gov/pubmed/18024864
  • Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecologic oncology. 105(1) : 211-7, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17239941
  • Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. The Yale journal of biology and medicine. 79(3-4) : 153-63, 2006. http://www.ncbi.nlm.nih.gov/pubmed/17940625
  • McAlpine JN, Kelly MG, O'malley DM, Azodi M, Coombe K, Schwartz PE, Rutherford TJ. Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies. Gynecologic oncology. 103(1) : 288-92, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16647749
  • Kelly MG Alvero AB Chen R Silasi DA Abrahams VM Chan S Visintin I Rutherford T Mor G. TLR-4 Signaling promotes tumor growth and Paclitaxel chemo-resistance in ovarian cancer. Canc Res. 66(7) : 3859-3868., 2006.
  • Alvero AB O’Malley D Brown D Kelly G Garg M Chen W Rutherford T Mor G. Molecular mechanism of Phenoxodiol-induced apoptosis in ovarian cancer cells. Cancer.. 106(3) : 599-608., 2006.
  • Alvero AB Chen W Sortotelli AC Schwartz P Rutherford TJ Mor G. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. J Soc Gynecol Investig. 13(2) : 145-152., 2006.
  • Kelly MG, O'malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecologic oncology. 98(3) : 353-9, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16005947
  • O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecologic oncology. 98(2) : 242-8, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15992916
  • Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC. Serum protein markers for early detection of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 102(21) : 7677-82, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15890779
  • Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, Garg M, Kamsteeg M, Rutherford T, Mor G. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncology research. 14(11-12) : 567-78, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15666998
  • Lane DB, Rutherford TJ, Taylor HS. HOXA10 expression in endometrial adenocarcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 25(5) : 264-9, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15627890
  • Zheng W Liang SX Yu H Rutherford TJ Chambers S Schwartz P. Endometrial glandular dysplasia: A newly defined precursor lesion of uterine serous papillary serous carcinoma. Part 1: Morhologic features. Int. J Surg Path.. 12(3) : 207-233., 2004.
  • Flick MB O’Malley DO Rutherford TJ Rodo S Kamsteeg M Hao XY Schwartz P Kacinski BM Mor M. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J. Soc. Gynecol. Invstig.. 11(4) : 253-259., 2004.
  • Collins Y Pejovic T Mor G Lele S Rutherford T McQuaid M Nowak N Odunsi K. Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinoma using cDNA microarray. Int. j. Mol. Med.. 14: 43-53., 2004.
  • Kelly MG O’Malley D Hui J Dziura J Rutherford TJ Azodi M Chambers SK Schwartz PE. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gyn Oncol.. 95: 469-473., 2004.
  • Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D, Mor G. Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 22(17) : 2611-20, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12730675
  • Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer research. 63(17) : 5573-81, 2003. http://www.ncbi.nlm.nih.gov/pubmed/14500397
  • Yalcin OT Rutherford TJ Chambers SK Chambers JT Schwartz PE. Vaginal intraepithelial neoplasia: treatment by carbon dioxide laser and risk factors for failure. Eur. J. Ob. Gyn.. 106: 64-68., 2003.
  • Chambers JT, Rutherford TJ, Schwartz PE, Carcangiu ML, Chambers SK, Baker L. A pilot study of topotecan in the treatment of serous carcinoma of the uterus. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 13(2) : 216-22, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12657127
  • Mor G Sapi E Abrahams VM Rutherford T Song J Hao XY Kohen F. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J. Immuno.. 170: 114-122., 2003.